EGFR and glioblastoma: However, in our data, there was no significant difference in MGMT methylation status (15.2% LGG has methylation and 30.8% GBM has methylation, P = 0.520), P53 mutational status (7.9% LGG was mutant, 7.6% GBM was mutant, P = 0.518), TERT promoter mutations (7.3% LGG was mutant, 9.8% GBM was mutant, P = 0.991), and EGFR amplification (4.2% LGG was amplification and 6.3% GBM was amplification, P=0.204) between the two groups of patients (Table 1).